Acrivon Therapeutics, Inc. (ACRV) AI Stock Analysis

• Market Cap: $94.98M
• Dividend Yield: N/A
• Average Volume (3M): 996.44K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.55
• Revenue Growth: N/A
• EPS Growth: 21.17%
• Country: US
• Employees: 75
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.47
• Shares Outstanding: 31,555,126
• 10 Day Avg. Volume: 442,853
• 30 Day Avg. Volume: 996,436
• PEG Ratio: 0.28
• Price to Book (P/B): 11.51
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -29.72
• Enterprise Value/Market Cap: -0.59
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 46.52
• Enterprise Value/Ebitda: 0.70
• 1Y Price Target: $10.00
• Price Target Upside: 238.98% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 59 Neutral
• Price Target: $3.00 ▲(1.69% Upside)

The score is primarily constrained by weak financial performance (no revenue, large and persistent losses, and significant ongoing cash burn), despite a low-debt balance sheet. Technicals are supportive with price above key moving averages and positive MACD. Recent positive clinical updates provide an additional tailwind, while valuation metrics are less informative due to negative earnings and no dividend.

Positive Factors

Proprietary AP3 precision oncology platform

Acrivon’s AP3-enabled platform that links therapies to predictive biomarkers is a durable competitive advantage. By enriching trials for likely responders, it raises probability of clinical success, improves trial efficiency, and supports differentiated, biomarker-driven commercialization strategies over time.

Compelling ACR-368 Phase 2b efficacy signals

Robust mid-stage efficacy (notably high ORRs in biomarker-positive and serous subgroups) strengthens the drug’s registrational potential and strategic positioning in endometrial cancer. Durable clinical signals can accelerate regulatory paths, partner interest, and long-term commercial prospects if confirmed in larger trials.

Low financial leverage reduces near-term solvency risk

Very low debt provides financial flexibility uncommon for clinical-stage biotechs, lowering bankruptcy and interest-rate risk. This balance sheet strength supports continued R&D investment and optionality for partnering or staged financings without immediate solvency pressure, a durable structural benefit.

Negative Factors

No revenue and widening operating losses

Persistent, growing operating losses reflect lack of commercial cash flow and heavy R&D spend. Over months, this erodes net worth and necessitates external financing; absent durable revenue, the company’s long-term viability hinges on successful trial outcomes or capital markets access, increasing execution risk.

High and increasing cash burn

Sustained negative operating and free cash flow at current magnitudes creates ongoing financing needs and potential dilution. Over a multi-month horizon this constrains strategic choices, limits ability to expand trials or infrastructure, and makes partnership or equity raises likely, pressuring shareholder value.

Clinical/regulatory timeline and execution risk

Key programs still need confirmatory trials and later-stage filings, with INDs and Phase 3 timelines stretching into 2026 and beyond. These long, binary development milestones mean value depends on future trial outcomes and regulatory approvals, sustaining execution and timing risk for investors and partners.

Acrivon Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

How the Company Makes Money

Acrivon Therapeutics, Inc. makes money primarily through the development and commercialization of its targeted oncology therapies. The company generates revenue by advancing its drug candidates through clinical trials with the aim of obtaining regulatory approval and subsequently marketing these therapies. Key revenue streams include potential licensing agreements, partnerships with other pharmaceutical companies, and milestone payments upon achieving specific clinical and regulatory milestones. Additionally, Acrivon may engage in collaborative research and development agreements to enhance its pipeline and broaden its market reach.

Acrivon Therapeutics, Inc. Financial Statement Overview

Summary

Acrivon Therapeutics, Inc. faces significant financial challenges with no revenue generation and increasing net losses. While the balance sheet shows a strong equity position, the cash flow is concerning due to heavy reliance on external financing. Overall, the financial health of the company needs improvement to ensure long-term viability.

Income Statement

The company has not generated any revenue over the analyzed period, which is a significant concern. Net income has consistently been negative, and losses have widened over time, with EBIT and EBITDA showing a similar trend. The lack of revenue and increasing losses place the company in a challenging financial position.

Balance Sheet

The company maintains a strong equity position relative to its liabilities, with a high equity ratio. However, the total debt has been managed at a low level, which is a positive sign. Despite these strengths, the consistent net losses reduce the overall value of the equity position.

Cash Flow

Operating cash flow has been consistently negative, indicating that the company is not generating enough cash to cover its operating expenses. Free cash flow is also negative, and the company relies heavily on financing activities to offset cash deficits. This reliance poses potential long-term sustainability risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-1.21M	-1.01M	-536.00K	0.00	0.00	-13.00K
EBITDA	-80.54M	-79.55M	-59.85M	-32.29M	-16.15M	-5.29M
Net Income	-81.75M	-80.56M	-60.39M	-31.17M	-16.24M	-5.31M
Balance Sheet
Total Assets	145.30M	196.59M	138.26M	181.23M	106.59M	2.19M
Cash, Cash Equivalents and Short-Term Investments	129.25M	179.48M	127.46M	127.75M	99.60M	1.58M
Total Debt	2.99M	3.65M	4.64M	4.96M	5.63M	58.00K
Total Liabilities	16.70M	19.80M	17.07M	10.75M	130.40M	10.60M
Stockholders Equity	128.60M	176.79M	121.19M	170.47M	-23.81M	-8.41M
Cash Flow
Free Cash Flow	-68.06M	-68.44M	-43.93M	-32.28M	-14.22M	-2.82M
Operating Cash Flow	-65.79M	-65.67M	-42.64M	-30.12M	-13.98M	-2.80M
Investing Cash Flow	58.99M	-51.77M	50.72M	-141.68M	-238.00K	-15.00K
Financing Cash Flow	-1.20M	121.03M	-1.55M	101.71M	112.22M	2.89M

Acrivon Therapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.95
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACRV, the sentiment is Positive. The current price of 2.95 is above the 20-day moving average (MA) of 2.47, above the 50-day MA of 2.31, and above the 200-day MA of 1.73, indicating a bullish trend. The MACD of 0.11 indicates Negative momentum. The RSI at 65.89 is Neutral, neither overbought nor oversold. The STOCH value of 55.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACRV.

Acrivon Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACRV	59 Neutral	$94.98M	-1.39	-50.23%	―	―	21.17%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CAMP	49 Neutral	$310.77M	-2.53	-172.70%	―	―	5.51%
ALGS	42 Neutral	$53.91M	-0.49	-141.82%	―	-55.88%	6.14%

Acrivon Therapeutics, Inc. Corporate Events

Acrivon Showcases Promising Phase 2b Oncology Data Update

On January 8, 2026, Acrivon Therapeutics hosted a corporate webcast and conference call to present updated clinical data for its lead oncology programs ACR-368 and ACR-2316, alongside broader AP3 pipeline developments. The company highlighted Phase 2b data from its ACR-368-201 (GOG-3082) trial in endometrial cancer, including an overall response rate of 39% for ACR-368 monotherapy in OncoSignature-positive patients and 26% for the ACR-368 plus ultra-low-dose gemcitabine combination, as well as particularly strong responses in biomarker-selected and serous endometrial cancer subgroups; these results, derived from non–QC’ed data as of December 4, 2025, support ACR-368’s registrational-intent pathway and reinforce Acrivon’s biomarker-driven strategy in a tumor type with significant unmet need, potentially strengthening its competitive positioning in precision oncology.

The most recent analyst rating on (ACRV) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Acrivon Therapeutics, Inc. stock, see the ACRV Stock Forecast page.

Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data

On January 8, 2026, Acrivon Therapeutics reported updated Phase 2b data for its CHK1/CHK2 inhibitor ACR-368 in endometrial cancer, with an interim analysis as of December 4, 2025 showing a 39% overall response rate in biomarker-positive monotherapy patients and a 44% rate in those with two or fewer prior lines of therapy; in the serous endometrial cancer subtype, confirmed response rates reached 67% in biomarker-positive patients and 52% across biomarker-positive and -negative subjects, prompting the company to refocus Arm 3 of the trial on serous patients with limited prior treatment and to expand this arm into more than 20 trial sites across Germany, Italy, France and Spain, with EU enrollment expected to begin in the first quarter of 2026 and overall Arm 3 enrollment completion targeted for the fourth quarter of 2026. The company also detailed progress in its broader pipeline, including initial Phase 1 results for ACR-2316, a potential first-in-class WEE1/PKMYT1 inhibitor, where 33 patients treated as of December 22, 2025 showed favorable tolerability and tumor shrinkage in 9 of 20 evaluable subjects—including partial responses in endometrial cancer, small cell lung cancer and squamous non-small cell lung cancer—and the nomination of ACR-6840, an AP3-derived CDK11 inhibitor, as its next development candidate with an investigational new drug application planned for late 2026, underscoring Acrivon’s drive to build a differentiated, AP3-enabled precision oncology franchise.

The most recent analyst rating on (ACRV) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Acrivon Therapeutics, Inc. stock, see the ACRV Stock Forecast page.